サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1411445

軸性脊椎関節炎市場：タイプ別、薬剤クラス別（抗リウマチ薬、グルココルチコイド、非ステロイド性抗炎症薬）、エンドユーザー別-2024-2030年の世界予測

Axial Spondyloarthritis Market by Type (Ankylosing Spondylitis, Non-Radiographic Axial Spondyloarthritis )), Drug Class (Anti-Rheumatic Drugs, Glucocorticoids, Non-steroidal anti-inflammatory Drugs ), End User - Global Forecast 2024-2030
出版日: | 発行: 360iResearch | ページ情報: 英文 180 Pages | 納期: 即日から翌営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
軸性脊椎関節炎市場：タイプ別、薬剤クラス別（抗リウマチ薬、グルココルチコイド、非ステロイド性抗炎症薬）、エンドユーザー別-2024-2030年の世界予測
出版日: 2024年01月16日
発行: 360iResearch
ページ情報: 英文 180 Pages
納期: 即日から翌営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

軸性脊椎関節炎市場規模は2023年に53億2,000万米ドルと推計され、2024年には56億8,000万米ドルに達し、CAGR7.42%で2030年には87億9,000万米ドルに達すると予測されます。

軸性脊椎関節炎の世界市場

主な市場の統計
基準年[2023］ 53億2,000万米ドル
予測年[2024］ 56億8,000万米ドル
予測年 [2030] 87億9,000万米ドル
CAGR（%） 7.42%
軸性脊椎関節炎 Market-IMG1

FPNVポジショニング・マトリックス

FPNVポジショニングマトリックスは軸性脊椎関節炎市場を評価する上で極めて重要です。事業戦略と製品満足度に関連する主要指標を調査し、ベンダーの包括的な評価を提供します。この綿密な分析により、ユーザーは各自の要件に沿った十分な情報に基づいた意思決定を行うことができます。評価に基づき、ベンダーは成功の度合いが異なる4つの象限に分類されます：フォアフロント（F）、パスファインダー（P）、ニッチ（N）、バイタル（V）です。

市場シェア分析

市場シェア分析は、軸性脊椎関節炎市場におけるベンダーの現状について、洞察に満ちた詳細な調査を提供する包括的なツールです。全体的な収益、顧客基盤、その他の主要指標についてベンダーの貢献度を綿密に比較・分析することで、企業の業績や市場シェア争いの際に直面する課題について理解を深めることができます。さらに、この分析により、調査対象基準年に観察された累積、断片化の優位性、合併の特徴などの要因を含む、この分野の競合特性に関する貴重な考察が得られます。このような詳細レベルの拡大により、ベンダーはより多くの情報に基づいた意思決定を行い、市場で競争優位に立つための効果的な戦略を考案することができます。

本レポートは、以下の側面に関する貴重な洞察を提供しています：

1-市場の浸透度：主要企業が提供する市場に関する包括的な情報を提示しています。

2-市場の開拓度：有利な新興市場を深く掘り下げ、成熟市場セグメントにおける浸透度を分析しています。

3-市場の多様化：新製品の発売、未開拓の地域、最近の開発、投資に関する詳細な情報を提供します。

4-競合の評価と情報：市場シェア、戦略、製品、認証、規制状況、特許状況、主要企業の製造能力などを網羅的に評価します。

5-製品開発およびイノベーション：将来の技術、研究開発活動、画期的な製品開発に関する知的洞察を提供します。

本レポートは、以下のような主要な質問に対応しています：

1-軸性脊椎関節炎市場の市場規模および予測は？

2-軸性脊椎関節炎市場の予測期間中に投資を検討すべき製品、セグメント、用途、分野は何か？

3-軸性脊椎関節炎市場における技術動向と規制の枠組みは？

4-軸性脊椎関節炎市場における主要ベンダーの市場シェアは？

5-軸性脊椎関節炎市場への参入に適した形態や戦略的手段は？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

  • 市場力学
    • 促進要因
      • 関節炎と関節痛の発生率の増加
      • 研究開発活動の増加
      • 関節炎の治療選択肢を拡大するための政府および民間企業による取り組み
    • 抑制要因
      • 製品および医薬品のリコールの発生率
    • 機会
      • 軸性脊椎関節炎の個別化されたケアの進歩
      • 軸性脊椎関節炎を標的とする新規生物製剤の出現
    • 課題
      • 医薬品の承認プロセスに関する厳しい規制
  • 市場セグメンテーション分析
  • 市場動向分析
  • 高インフレの累積的影響
  • ポーターのファイブフォース分析
  • バリューチェーンとクリティカルパス分析
  • 規制の枠組み

第6章 軸性脊椎関節炎の市場：タイプ別

  • 強直性脊椎炎（AS）
  • 非X線軸性脊椎関節炎（nr-axSpA）

第7章 軸性脊椎関節炎の市場：薬剤クラス別

  • 抗リウマチ薬
  • グルココルチコイド
  • 非ステロイド性抗炎症薬（NSAIDs）

第8章 軸性脊椎関節炎の市場：エンドユーザー別

  • 学術調査機関
  • クリニック
  • 病院
  • リハビリテーションセンター

第9章 南北アメリカの軸性脊椎関節炎の市場

  • アルゼンチン
  • ブラジル
  • カナダ
  • メキシコ
  • 米国

第10章 アジア太平洋地域の軸性脊椎関節炎の市場

  • オーストラリア
  • 中国
  • インド
  • インドネシア
  • 日本
  • マレーシア
  • フィリピン
  • シンガポール
  • 韓国
  • 台湾
  • タイ
  • ベトナム

第11章 欧州・中東・アフリカの軸性脊椎関節炎の市場

  • デンマーク
  • エジプト
  • フィンランド
  • フランス
  • ドイツ
  • イスラエル
  • イタリア
  • オランダ
  • ナイジェリア
  • ノルウェー
  • ポーランド
  • カタール
  • ロシア
  • サウジアラビア
  • 南アフリカ
  • スペイン
  • スウェーデン
  • スイス
  • トルコ
  • アラブ首長国連邦
  • 英国

第12章 競合情勢

  • FPNVポジショニングマトリクス
  • 市場シェア分析：主要企業別
  • 競合シナリオ主要企業別の分析

第13章 競争力のあるポートフォリオ

  • 主要な企業プロファイル
    • Abbott Laboratories
    • AbbVie Inc.
    • Amgen Inc.
    • Eli Lilly and Company
    • Galapagos NV
    • Inmagene Biopharmaceuticals
    • Johnson & Johnson Services, Inc.
    • Merck & Co., Inc.
    • Novartis AG
    • Pfizer Inc.
    • UCB S.A.
  • 主要な製品ポートフォリオ

第14章 付録

  • ディスカッションガイド
  • ライセンスと価格について
図表

LIST OF FIGURES

  • FIGURE 1. AXIAL SPONDYLOARTHRITIS MARKET RESEARCH PROCESS
  • FIGURE 2. AXIAL SPONDYLOARTHRITIS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. AXIAL SPONDYLOARTHRITIS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. AXIAL SPONDYLOARTHRITIS MARKET DYNAMICS
  • FIGURE 7. AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 8. AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
  • FIGURE 10. AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2023 VS 2030 (%)
  • FIGURE 12. AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. AMERICAS AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 14. AMERICAS AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. UNITED STATES AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 16. UNITED STATES AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. ASIA-PACIFIC AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 18. ASIA-PACIFIC AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. AXIAL SPONDYLOARTHRITIS MARKET, FPNV POSITIONING MATRIX, 2023
  • FIGURE 22. AXIAL SPONDYLOARTHRITIS MARKET SHARE, BY KEY PLAYER, 2023

LIST OF TABLES

  • TABLE 1. AXIAL SPONDYLOARTHRITIS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. AXIAL SPONDYLOARTHRITIS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 6. AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY ANKYLOSING SPONDYLITIS (AS), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 7. AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS (NR-AXSPA)), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 8. AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 9. AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY ANTI-RHEUMATIC DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY GLUCOCORTICOIDS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 13. AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY REHABILITATION CENTER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. AMERICAS AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 18. AMERICAS AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 19. AMERICAS AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 20. AMERICAS AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 21. ARGENTINA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 22. ARGENTINA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 23. ARGENTINA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 24. BRAZIL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 25. BRAZIL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 26. BRAZIL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 27. CANADA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 28. CANADA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 29. CANADA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 30. MEXICO AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 31. MEXICO AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 32. MEXICO AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 33. UNITED STATES AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 34. UNITED STATES AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 35. UNITED STATES AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 36. UNITED STATES AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 37. ASIA-PACIFIC AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 38. ASIA-PACIFIC AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 39. ASIA-PACIFIC AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 40. ASIA-PACIFIC AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 41. AUSTRALIA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 42. AUSTRALIA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 43. AUSTRALIA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 44. CHINA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 45. CHINA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 46. CHINA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 47. INDIA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 48. INDIA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 49. INDIA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 50. INDONESIA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 51. INDONESIA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 52. INDONESIA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 53. JAPAN AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 54. JAPAN AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 55. JAPAN AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 56. MALAYSIA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 57. MALAYSIA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 58. MALAYSIA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 59. PHILIPPINES AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. PHILIPPINES AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 61. PHILIPPINES AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 62. SINGAPORE AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 63. SINGAPORE AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 64. SINGAPORE AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 65. SOUTH KOREA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. SOUTH KOREA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 67. SOUTH KOREA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 68. TAIWAN AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 69. TAIWAN AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 70. TAIWAN AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 71. THAILAND AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. THAILAND AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 73. THAILAND AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 74. VIETNAM AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 75. VIETNAM AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 76. VIETNAM AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 77. EUROPE, MIDDLE EAST & AFRICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. EUROPE, MIDDLE EAST & AFRICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 79. EUROPE, MIDDLE EAST & AFRICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 81. DENMARK AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. DENMARK AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 83. DENMARK AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 84. EGYPT AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 85. EGYPT AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 86. EGYPT AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 87. FINLAND AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. FINLAND AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 89. FINLAND AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 90. FRANCE AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 91. FRANCE AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 92. FRANCE AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 93. GERMANY AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. GERMANY AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 95. GERMANY AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 96. ISRAEL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 97. ISRAEL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 98. ISRAEL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 99. ITALY AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. ITALY AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 101. ITALY AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 102. NETHERLANDS AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 103. NETHERLANDS AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 104. NETHERLANDS AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 105. NIGERIA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 106. NIGERIA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 107. NIGERIA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 108. NORWAY AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 109. NORWAY AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 110. NORWAY AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 111. POLAND AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 112. POLAND AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 113. POLAND AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 114. QATAR AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 115. QATAR AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 116. QATAR AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 117. RUSSIA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 118. RUSSIA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 119. RUSSIA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 120. SAUDI ARABIA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 121. SAUDI ARABIA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 122. SAUDI ARABIA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 123. SOUTH AFRICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 124. SOUTH AFRICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 125. SOUTH AFRICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 126. SPAIN AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 127. SPAIN AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 128. SPAIN AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 129. SWEDEN AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 130. SWEDEN AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 131. SWEDEN AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 132. SWITZERLAND AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 133. SWITZERLAND AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 134. SWITZERLAND AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 135. TURKEY AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 136. TURKEY AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 137. TURKEY AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 138. UNITED ARAB EMIRATES AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 139. UNITED ARAB EMIRATES AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 140. UNITED ARAB EMIRATES AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 141. UNITED KINGDOM AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED KINGDOM AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED KINGDOM AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 144. AXIAL SPONDYLOARTHRITIS MARKET, FPNV POSITIONING MATRIX, 2023
  • TABLE 145. AXIAL SPONDYLOARTHRITIS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 146. AXIAL SPONDYLOARTHRITIS MARKET LICENSE & PRICING
目次
Product Code: MRR-5C6F41F5AF80

[180 Pages Report] The Axial Spondyloarthritis Market size was estimated at USD 5.32 billion in 2023 and expected to reach USD 5.68 billion in 2024, at a CAGR 7.42% to reach USD 8.79 billion by 2030.

Global Axial Spondyloarthritis Market

KEY MARKET STATISTICS
Base Year [2023] USD 5.32 billion
Estimated Year [2024] USD 5.68 billion
Forecast Year [2030] USD 8.79 billion
CAGR (%) 7.42%
Axial Spondyloarthritis Market - IMG1

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Axial Spondyloarthritis Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Axial Spondyloarthritis Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Axial Spondyloarthritis Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AbbVie Inc., Amgen Inc., Eli Lilly and Company, Galapagos NV, Inmagene Biopharmaceuticals, Johnson & Johnson Services, Inc., Merck & Co., Inc., Novartis AG, Pfizer Inc., and UCB S.A..

Market Segmentation & Coverage

This research report categorizes the Axial Spondyloarthritis Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Type
    • Ankylosing Spondylitis (AS)
    • Non-Radiographic Axial Spondyloarthritis (nr-axSpA))
  • Drug Class
    • Anti-Rheumatic Drugs
    • Glucocorticoids
    • Non-steroidal anti-inflammatory Drugs (NSAIDs)
  • End User
    • Academic Research Institutes
    • Clinics
    • Hospital
    • Rehabilitation Center
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Axial Spondyloarthritis Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Axial Spondyloarthritis Market?

3. What are the technology trends and regulatory frameworks in the Axial Spondyloarthritis Market?

4. What is the market share of the leading vendors in the Axial Spondyloarthritis Market?

5. Which modes and strategic moves are suitable for entering the Axial Spondyloarthritis Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Limitations
  • 1.7. Assumptions
  • 1.8. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Axial Spondyloarthritis Market, by Region

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising incidences of arthritis and joint pain
      • 5.1.1.2. Growing number of research and development activities
      • 5.1.1.3. Efforts by government and private players to expand treatment options for arthritis
    • 5.1.2. Restraints
      • 5.1.2.1. Incidences of product and drug recall
    • 5.1.3. Opportunities
      • 5.1.3.1. Advances in personalized care for axial spondyloarthritis
      • 5.1.3.2. Emergence of novel biologic agents targeting axial spondyloarthritis
    • 5.1.4. Challenges
      • 5.1.4.1. Stringent regulations concerning the drug approval process
  • 5.2. Market Segmentation Analysis
  • 5.3. Market Trend Analysis
  • 5.4. Cumulative Impact of High Inflation
  • 5.5. Porter's Five Forces Analysis
    • 5.5.1. Threat of New Entrants
    • 5.5.2. Threat of Substitutes
    • 5.5.3. Bargaining Power of Customers
    • 5.5.4. Bargaining Power of Suppliers
    • 5.5.5. Industry Rivalry
  • 5.6. Value Chain & Critical Path Analysis
  • 5.7. Regulatory Framework

6. Axial Spondyloarthritis Market, by Type

  • 6.1. Introduction
  • 6.2. Ankylosing Spondylitis (AS)
  • 6.3. Non-Radiographic Axial Spondyloarthritis (nr-axSpA))

7. Axial Spondyloarthritis Market, by Drug Class

  • 7.1. Introduction
  • 7.2. Anti-Rheumatic Drugs
  • 7.3. Glucocorticoids
  • 7.4. Non-steroidal anti-inflammatory Drugs (NSAIDs)

8. Axial Spondyloarthritis Market, by End User

  • 8.1. Introduction
  • 8.2. Academic Research Institutes
  • 8.3. Clinics
  • 8.4. Hospital
  • 8.5. Rehabilitation Center

9. Americas Axial Spondyloarthritis Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Axial Spondyloarthritis Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Axial Spondyloarthritis Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. FPNV Positioning Matrix
  • 12.2. Market Share Analysis, By Key Player
  • 12.3. Competitive Scenario Analysis, By Key Player

13. Competitive Portfolio

  • 13.1. Key Company Profiles
    • 13.1.1. Abbott Laboratories
    • 13.1.2. AbbVie Inc.
    • 13.1.3. Amgen Inc.
    • 13.1.4. Eli Lilly and Company
    • 13.1.5. Galapagos NV
    • 13.1.6. Inmagene Biopharmaceuticals
    • 13.1.7. Johnson & Johnson Services, Inc.
    • 13.1.8. Merck & Co., Inc.
    • 13.1.9. Novartis AG
    • 13.1.10. Pfizer Inc.
    • 13.1.11. UCB S.A.
  • 13.2. Key Product Portfolio

14. Appendix

  • 14.1. Discussion Guide
  • 14.2. License & Pricing